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Abstract
Background: Dietary interventions including consumption of flavonoids, plant compounds found in certain foods,
may have the ability to improve fatigue. However, to date, no well-designed intervention studies assessing the role
of flavonoid consumption for fatigue management in people with MS (pwMS) have been performed. The hypothesis
is that the consumption of a flavonoid-rich pure cocoa beverage will reduce fatigue in pwMS. The aim of this study is
to determine the feasibility and potential outcome of running a trial to evaluate this hypothesis.
Methods: Using a randomised (1:1) double-blind placebo-controlled feasibility study, 40 men and women (20 in each
trial arm) with a recent diagnosis (< 10 years) of relapsing and remitting MS (RRMS) and who are over 18 years of age
will be recruited from neurology clinics and throughout the Thames Valley community. During a 6-week nutrition
intervention period, participants will consume the cocoa beverage, high flavonoid or low flavonoid content, at
breakfast daily. At baseline, demographic factors and disease-related factors will be assessed. Fatigue, activity and
quality of life, in addition to other measures, will be taken at three visits (baseline, week 3 and week 6) in a
university setting by a researcher blinded to group membership. Feasibility and fidelity will be assessed through
recruitment and retention, adherence and a quantitative process evaluation at the end of the trial.
We will describe demographic factors (age, gender, level of education) as well as disease-related factors (disease
burden scores, length of time diagnosed with MS) and cognitive assessment, depression and quality of life and
general physical activity in order to characterise participants and determine possible mediators to identify the
processes by which the intervention may bring about change. Feasibility (recruitment, safety, feasibility of
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implementation of the intervention and evaluation, protocol adherence and data completion) and potential for
benefit (estimates of effect size and variability) will be determined to inform future planned studies. Results will
be presented using point estimates, 95% confidence intervals and p values. Primary statistical analysis will be on
an intention-to-treat basis and will use the complete case data set.
Discussion: We propose that a flavonoid-enriched cocoa beverage for the management of fatigue will be well
received by participants. Further, if it is implemented early in the disease course of people diagnosed with RRMS,
it will improve mobility and functioning by modifying fatigue.
Trial registration: Registered with ISRCTN Registry. Trial registration No: ISRCTN69897291; Date April 2016
Keywords: Fatigue, Cocoa, Flavonoids, Diet, Multiple sclerosis,
Background
Fatigue is one of the most common and debilitating
symptoms experienced in people with MS (pwMS),
and it is thought that as many as 53–90% of pwMS
suffer from fatigue [1].
Currently, there are no highly effective treatments
for fatigue in MS; however, simple lifestyle interven-
tions including diet approaches may be beneficial for
reducing the extent of fatigue [2].
The physiological causes of fatigue are complex, in-
cluding neural, inflammatory and metabolic mecha-
nisms, and can result in further changes including
increased cytokine production, oxidative stress and al-
tered glutamate/glutathione levels in the brain, all
thought to contribute to fatigue [3–7]. Certain com-
pounds in foods called flavonoids may be used to
exert drug-like effects in reducing the severity of fa-
tigue by tackling these mechanisms, and these foods
are becoming increasingly popular for their alleged
ubiquitous benefits on health, the ageing process and
neurological function [8].
Dark chocolate containing 70% or more cocoa solids is
well known for its high antioxidant and flavonoid content.
Over a 4-week period, dark chocolate consumption has
been shown to improve fatigue in those with chronic
fatigue syndrome (CFS) which could part due to the
improvements in immune function that is often seen with
the condition [9]. Also, results from a small randomised
controlled pilot study and using a short-term cocoa inter-
vention suggested an increase in sleep quality and reduction
in fatigue [10].
Alterations in inflammatory and immunological
function have been shown to precede relapses in
those with relapsing and remitting MS (RRMS) [11]
and have been thought to contribute to the early
symptoms of fatigue [12–14]. This has therefore
raised the question as to whether alleviating these
markers may improve the fatigue experienced early
on in those with the disease and improved mobility
and physical activity [15, 16].
This study sets out to determine the potential benefit and
feasibility of implementing a flavonoid dietary intervention
that was co-designed with pwMS. We propose that a single
drink of flavonoid-rich cocoa taken each morning
over a 6-week period will be feasible and acceptable
for pwMS. We will also estimate the variation and
change in fatigue to allow for a power calculation to
be made for a larger trial. In addition, there is a
process evaluation of both quantitative and qualitative
components. The study uses a randomised, parallel
group controlled design where participants will either be
supplied with cocoa rich in flavonoids or a low-flavonoid
cocoa drink that looks and tastes the same.
Objectives
To determine whether the current study design is feas-
ible to undertake, and to estimate the potential benefit
and number of participants needed for a phase III trial,
the following key objectives will be assessed from results
of this study:
1. The acceptability of the study design and dietary
intervention to participants
2. Recruitment rate and reasons for non-recruitment
3. Follow-up rate and reasons for loss to follow-up
4. Level of adherence to the protocol, including the
process of randomisation
5. A parallel process evaluation to explore participant
acceptance, potential concerns and overall process
flow of the proposed intervention
6. Data acquisition rate, amount of missing data and
reasons for loss
7. To determine the variability and effect size of the
outcome measures, especially on fatigue.
Methods
Setting
All testing will take place at the Oxford Brookes
University (OBU), Oxford, UK, except for home visits
in which participants have the option for researchers
Coe et al. Pilot and Feasibility Studies  (2018) 4:35 Page 2 of 11
to visit their homes to collect measures. The inter-
vention will be self-directed and take place in the
home of each participant. Testing will take place in
the morning between 7.30 and 10 a.m.
Recruitment
PwMS will be recruited from the Oxford University
Hospitals National Health Service (NHS) Trust (John
Radcliffe Hospital site), Milton Keynes Hospital, Royal
Berkshire Hospital or Buckingham Hospital by nurses
and clinicians at each site who work with MS
patients, through a list of those who have consented
to being contacted about clinical trials. Potentially
eligible participants who are interested in the study
will have their contact details collected by the lead
researcher who will provide further information. Local
MS Society branches will also be made aware of the
trial and given contact details, and an advertisement
for the study along with the participant information
sheet will be made available on the MS Society web-
site. Individuals will then be able to self-refer to the
study.
Trial design
This is a mixed methodology, randomised double-
blind placebo-controlled feasibility trial and process
evaluation. As a feasibility trial, aspects of feasibility
will be determined and estimates of effect size and
measured variability will be calculated to inform
future planned studies. The intervention will last a
total of 6 weeks. Participants will be assessed at baseline
on enrolment into the trial. Randomisation to allocate
participants to either intervention or control group
(1:1) will be performed immediately following the
baseline assessment, and intervention delivery will
begin directly after the baseline assessment. Participants
will then be reassessed at 3 and 6 weeks (assessments
2 and 3, respectively) after the baseline. At assessment 2,
the lead researcher accompanied by one of the research
team will offer to travel to the home of the participants to
take measures, if they so wish (Fig. 1). This is to reduce
patient burden with the aim to increase recruitment and
retention rate.
Participants
Participants will be considered eligible for the study if
they present with the following criteria:
1. Aged 18 years or more with a new clinical diagnosis
of RRMS within the past 10 years
2. Those who are treatment naïve or taking first-line
disease-modifying treatments (DMTs) (glatiramer
acetate, interferon beta, teriflunomide and dimethyl
fumarate, but also alemtuzumab and Tysabri if used
as first-line treatments)
3. No relapse or sudden change in their MS symptoms
within the previous 3 months
4. Do not have contraindications to providing a blood
sample
5. No contraindications to tolerating the cocoa drink
6. A fatigue measure of greater than 4 on the Fatigue
Severity Scale (FSS) [17]
7. No other conditions that may be associated with
fatigue, e.g. anaemia
8. No clinical diagnosis of depression
9. An Expanded Disability Status Scale (EDSS) score of
< 4.5
10.Sufficient mental capacity to consent as determined
by the researchers
11.Able to walk with or without a walker for at least
16 m
12.No condition affecting the central nervous system
other than MS (however, migraine is allowed)
13.Not pregnant or lactating
14.No objection to the researchers contacting their
general practitioner and neurologist
Participants must also not be on any other clinical trial
during the study.
Consent
Participants will be emailed or personally administered
an information sheet by clinicians at one of the hos-
pital sites or by a member of the research team and
given at least 24 h to consider the information. An
eligibility check will be performed over the telephone
by one of the researchers. During the telephone call
and at the baseline assessment, potential participants
will be allowed to ask questions if they wish to par-
ticipate in the study, and enrolment into the trial will
be immediately allocated. Informed consent will be
obtained by members of the research team at the
baseline assessment, who will be trained in taking
consent and in good clinical practice. Recruitment
began in May 2016.
Withdrawal of consent will have no detrimental im-
pact on current and future treatment, and those tak-
ing consent will ensure that participants fully
understand this. If a participant was to lose his/her
capacity to consent during the trial, the participant
will be withdrawn, no further procedures will be car-
ried out on them and no new personal data will be
collected. Data that has already been collected in rela-
tion to the participant may be retained and used for
the purposes for which consent has already been
given, provided they are effectively anonymised and
no longer identifiable to the research team.
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Retention
We will make every effort to reduce loss to follow-up.
One primary contact within each centre will contact all
participants and act as liaison with the blinded assessor.
The primary contact person will obtain information about
the participants’ preferred method of contact (text, tele-
phone, email and letter) and contact them using this pre-
ferred method when possible. They will also ask the
participant for details of a nominated person who can be
contacted if the team is unable to make contact with
them, and we will retain details of the participant’s general
practitioner. Contact details will be updated if applicable
at each assessment. All appointments will be made at the
research participant’s convenience wherever possible. If an
appointment is missed we will try to rearrange this on two
more occasions.
Screening
A screening log will be kept at OBU where details of num-
bers of people who were approached about the trial, eligi-
bility and whether consent to be contacted was given or
declined will be recorded. A log of any individuals, who
declined at the initial consent stage, or consented but
failed screening, will also be kept. A case report form
(CRF) will be completed for all consented individuals,
which will include details of nominated persons (e.g.
mother or friend) to facilitate participant follow-up.
Outcomes
The primary aim of this study is to assess feasibility
of the dietary intervention in terms of adherence,
safety and process. This will be achieved through the
documentation of adherence and any adverse events
(AEs), as well as any health-related changes such as
gastrointestinal disturbances that may occur during
the intervention period. Duration of participation and
dropout from the intervention will also be recorded.
In order to assess benefits, a range of outcomes will
be obtained. Outcome measures include
1. Levels of physical activity: wearable activity monitors
(worn like a watch) [18] and the Physical Activity
Scale for the Elderly (PASE) questionnaire [19]
Fig. 1 Trial schema and participant flow diagram
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2. Dietary patterns assessed by a nutritionist: three
24-h dietary records [20]
3. Fatigue levels: FSS, Neuro-QOL [21], and
during the intervention, a Numerical Rating
Scale (NRS) scored from 1 to 10, three times
daily which classifies no fatigue as a 1 and very
fatigued as a 10.
4. Fatigability: performance on 6-min walk test
(physical) [22] and the Adult Memory and Informa-
tion Processing Battery (AMIBP; mental) [23]
5. Blood markers of inflammation: TNF-alpha, reduced
glutathione, a marker of antioxidant status and lipid
peroxidation
6. Health descriptives: EQ5D5L [24] and the
Preference-Based Multiple Sclerosis Index (PBMSI)
[25], basic health questionnaire, Barthel ADL Index
(BI) [26] and Hospital Anxiety and Depression Scale
(HADS) [27]
Demographic factors and background factors will be
assessed at baseline: medication, age, gender, level of
education, type of MS, duration of disease, height,
weight and leg length will be assessed at baseline. Partic-
ipants will be stratified for gender and whether they are
on first-line disease-modifying treatments or not.
Table 1 summarises the questionnaires that will be ad-
ministered throughout the trial and at which visits these
measures will be collected.
Intervention
Cocoa
Participants will consume the drink (intervention or
control) in their homes, after a 10-h overnight fast at the
same time each morning. After the consumption of the
drink (18 g of cocoa in 200 ml heated rice milk), they
will wait an additional 30-min period before consuming
any other food or beverage. They will be instructed to
take their normal medication and to follow their diet as
usual. On the days when assessments take place at the
university, participants will arrive fasted and will therefore
not consume the cocoa that day. The cocoa drinks (inter-
vention and control) are designed to differ only in
Table 1 Outcome measures
Domain to be measured Outcome measure(s) Time required When
Measures of overall health and questionnaires
1. Health questionnaire and
health assessment
General medicine use/
health problems, etc.
10 min 1
2. Global fatigue Neuro quality of life 5 min 1, 2, 3
3. Limitations in daily activity Barthel Activities in
Daily Living Index
5 min 1
4. Quality of life measure EuroQOL 5D5L and
Problem Based Multiple
Sclerosis Index
5 min 1, 2, 3
5. Dietary recall Monitor diet patterns 10 min 1, 2, 3
6. Consent Verbal followed by
written
10 min 1
8. Speed of information
processing
The Adult Memory and
Information Processing
Battery
5 min 1, 2, 3
9. Depression Hospital Anxiety and
Depression Scale
5 min 1, 2, 3
10. Physical activity Physical Activity Survey
for the Elderly
10 min 1
11. Fatigue Fatigue Severity Scale 5 min 1
Measures of activity and fatigue
11. 6-min walk Fatigue 6 min 1, 3
12. Accelerometer Activity 2 weeks and 3 days throughout
intervention
–
13. Numerical Rating Scale for fatigue Fatigue 3 times daily for 6 weeks –
Measures of plasma markers
14. Venous blood samples Inflammation, oxidative
stress, antioxidant capacity
of plasma
5 min 1, 2, 3
1 = baseline assessment; 2 = assessment 2 (3 weeks); 3 = assessment 3 (6 weeks)
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flavonoid content (low {19 mg cocoa flavonoids} versus
high {200 mg cocoa flavonoids} flavonoid content). The
flavonoid-rich pure cocoa drink will be matched to the
control drink for macronutrients, theobromine and caf-
feine and will be as identical as possible in appearance and
taste to ensure double blinding. Cocoa powder will be
provided in air-tight individual sachets, and participants
will receive 21 packets at the baseline visit and again at as-
sessment 2; the contents will need to be added to a mug,
and heated rice milk will be added prior to consumption.
Instructions on preparation will be provided to ensure all
participants follow the same protocol. Unused cocoa con-
tent will be saved and collected by the researcher.
Fatigue
Fatigue will be measured at baseline using the FSS. If
participant scores a 4 or above and thus fulfils the cri-
teria to take part in the trial, he or she will then wait
3 days before beginning the intervention. On the fourth
day, the participant will begin consuming the coca drink.
Directly after the consumption of the drink, participants
will rate on an NRS their level of fatigue. This will be
followed by two additional measures recorded at 3 p.m.
and 8 p.m., daily for the 6 weeks. They will be asked to
reply to the text message with a score of fatigue from 1
to 10, 1 being no fatigue and 10 being very fatigued.
Smart phones will be provided to those who do not have
them and collected after the trial termination, and ease
and acceptability of phone use will be documented.
Walking endurance will be measured a total of two
times (baseline and assessment 3) using a 6-min walk
test [22], and sensors will be worn to measure gait dur-
ing the walk. Gait measurements will be collected via an
inertial measurement unit (IMU) [28, 29] attached to
the lower spine (lumbar 4 region) by double-sided adhe-
sive tape. Participants are instructed to walk over a 14-m
walkway free of obstacles at their self-selected walking
speed. Walking speed will be derived from IMU data by
using well-established validated algorithms [28, 29].
Blood measures
Participants will have fasting blood samples taken by a
trained phlebotomist a total of three times throughout
the trial. Blood samples will be collected at OBU or at
the home of the participant (assessment 2). Blood collec-
tion will be in the morning when the participant is
fasted, time will be recorded at the first collection and
collection for subsequent assessments will be taken
within an hour of this time. Blood will be labelled and
frozen for future analysis following standard operating
procedures (SOPs) for storage of plasma at OBU. Fasting
plasma glutathione (oxidised and reduced) will serve as a
measure of adherence to the consumption of the drink
throughout the trial. Changes in levels of the
inflammatory marker TNF-alpha (ELISA assay kit) and
lipid peroxidation (MCA reaction assay) will also be mea-
sured as markers of inflammation and oxidative stress, re-
spectively, at the same time points. Assays for these
individual markers will be purchased from Sigma-Aldrich
(UK) and will be analysed using facilities available at OBU.
Outcome measures will be determined from venous blood
(total at each assessment no more than 50 ml) samples
taken three times throughout the intervention—baseline
assessments 1 and 2, after an overnight (10–12-h) fast.
These measures will determine the change in metabolic
parameters throughout the trial and will also allow for ad-
verse changes made possible due to the consumption of
the control drink. In addition, compliance and willingness
to have blood measures taken will be documented.
Activity
Accelerometers will be worn for 3 days before starting the
cocoa and then for the third and sixth weeks (7 days each,
17 days in total) after starting. They will sample data at
25 Hz [18], and data will be averaged for each day. Partici-
pants will be reminded to initiate wearing the accelerome-
ters by the lead researcher via text messages. The
acceptance and adherence to wearing the accelerometers
during this time will be assessed at the final assessment.
Diet
A total of three 24-h dietary recalls will be administered
to provide information about the diet of each participant
and to determine any changes that may take place
throughout the study. This method is less burdensome
for patients than a 7-day food record diary yet will still
provide an overall pattern in dietary behaviour through-
out the study. Total energy intake is a potential con-
founder of the study and will therefore be corrected for
in the analysis. We advise participants not to change
their habitual diet and exercise regimes during the trial.
Sample size
A sample size of 40 pwMS was deemed appropriate
to address feasibility and determine variability of out-
come measures [30–32] for a follow-on trial based on
a 12-month recruitment period. Approximately five
potentially eligible patients with recently diagnosed
RRMS attend the clinic at the hospital per week, of
which three will potentially fit the inclusion criteria
of the study. Considering a recruitment rate of ap-
proximately 1.5 patients per week (50%), this would
enable a minimum sample of 40 pwMS. The sample
size of ≥ 30 also allows for assumptions from the cen-
tral limit theorem in relation to representation within
this group of RRMS with fatigue and should be easily
recruitable within the timeframe.
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Data management
All work undertaken as part of this trial will comply with
the Research Governance Framework for Health and Social
Care UK and the OBU Research Governance Framework.
All participant identification and referral procedures as
well as procedures for data storage, processing and man-
agement will comply with the Data Protection Act 1998.
All assessment data will be collected face-to-face using
paper data collection forms. AE forms will be collected in
person by one of the research team at OBU named in the
delegation log. The retention period complies with guide-
lines set out by the OBU Research Governance Frame-
work. Any individual who discontinues or deviates from
the intervention will still have their data included in the
data analysis.
Safety monitoring
All chemicals required for assays will be purchased from
Sigma-Aldrich, UK. SOPs have been approved by OBU and
will be utilised for conducting all outcome assessments.
There are no expected serious adverse events (SAEs)
in this study. The proposed procedures carry minimal
risk to participants, and their care and comfort will be
ensured throughout. This research will be performed in
accordance with the International Conference on
Harmonisation-Good Clinical Practice (ICH-GCP) stan-
dards. National Research Ethics Service ethical approval
will be sought and confirmed before the start of the trial.
The study will be overseen by a steering committee who
will act as the data-monitoring committee to consider
AEs and/or lack of adherence to the protocol (objection
to having blood samples taken, lack of tolerance to the
control/test drink).
Randomisation
After recruitment, confirmation of eligibility, giving con-
sent and collection of baseline data, patients will be reg-
istered and then randomised into one of the two groups,
either the control or the test cocoa group. Participants
recruited to the study will be randomly allocated the
next available study number by the blinded assessor,
with 20 participants in each group. The unblinded re-
searcher will randomise participants into the control or
intervention group using a computer-generated random-
isation groups stratified for gender and DMTs.
Blinding
This is a double-blind trial. One of the researchers on
the trial will have access to the randomisation list, in
which she will allocate participants randomly to either
group. Each cocoa pack will contain a unique three-digit
code, which will be determined by the unblinded researcher
who will be able to trace the codes back to the cocoa group.
All data collection will be conducted by a team of blinded
assessors specifically trained in the methodology utilised for
the collection of physical activity and functional assess-
ments. Records of incidents where blinding is broken will
be kept. All researchers who have contact with the partici-
pants will be blinded, including the main researcher on the
trial. The main researcher and the statistician will remain
blinded until after data analysis. Also, at the end of the
intervention but before disclosure, participants will report
their opinions of which group they believe they have been
allocated to. A SAE could result in unblinding; however,
this is unlikely as the principal investigator (PI) and the
consultant medic on the trial will assess all AEs and SAEs
and will make a decision of the action.
Process evaluation
Upon exiting the study at assessment 3, each patient will
be interviewed about queries regarding the intervention
process, ease of adherence, tolerance and acceptability of
the flavonoid drink and collection of outcome measures,
and asked about any other issues or concerns arising
from the trial. Participants will be asked their opinion
on the importance of the research question proposed to
inform future trials. We will also attempt to contact any
participants who drop out of the intervention to ascer-
tain reasons for discontinuing. Topics will include chal-
lenges to intervention delivery, perceived successes,
barriers to implementation and suggestions on how to
improve the intervention process. All participants who
complete the trial only will be interviewed.
We will employ standard thematic analysis techniques.
The transcripts of interviews will be closely examined to
identify themes and categories. Codes will be applied to these
broad themes, which will then be broken down further into
sub-codes. Agreement on concepts and coding will be
sought between members of the research team to ensure reli-
ability. We will identify commonly expressed themes as well
as unusual cases. A proportion of the data (20%) will be
coded by two different team members to check on reliability
of the coding scheme. The process of data collection and
data analysis will be iterative, so that new themes emerge,
and we will incorporate them into subsequent interview
schedules. Process evaluation will include frequencies for ad-
hering to the intervention, session content and progression
which will be analysed descriptively with confidence intervals
and regression where possible.
Ethical and regulatory considerations
The trial has received approval from an NHS Research
Ethics Committee (NHS REC, 16/WM/0134) for approval.
Site-specific approvals for NHS PIC sites have been ob-
tained. This is consistent with the requirements of OBU,
who has agreed to act as the trial sponsor. All protocol
and trial amendments (both minor and major) will be sub-
mitted through the ethics committee and, once approved,
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will be communicated to the sponsor and funding body
and to the steering committee. The confidentiality of par-
ticipants will be preserved in accordance with the Data
Protection Act 1998. All participants will be allocated a
unique identifier, and all trial data collected will be held in
a linked anonymised form. Identifiable information will be
stored separately from trial data. The randomisation will
be held by a member of the research team who will over-
see the trial but will not be involved in data collection or
analysis. Group allocation will be referred by this same
member and will ensure double blinding.
Dissemination policy
Results of this trial will be reported in the first instance
to the funders and then communicated to participants
and relevant health professionals in a series of open ac-
cess publications within 9 months of the end of the data
collection. Authorship will follow the trial publication
policy that has been developed based on British Medical
Journal rules on authorship and contributorship. All
publications will be deposited in the university open ac-
cess forum for publications and, as much as possible,
will be published in open access journals and will be
open access on demand. The BMJ guidelines on writing
authorship will be adhered to, and all members on the
trial steering committee will sign and agree.
Discontinuing
Participants will be advised to discontinue the trial if
they find consuming the cocoa unacceptable or if con-
suming the cocoa is associated with in any related or un-
related AEs. Discontinuation of the trial will ultimately
be decided by the PI and consultant medic.
Auditing
The trial is open to auditing either through NHS govern-
ance or through the university’s Centre for Movement,
Occupational and Rehabilitation Sciences governance
committee.
Statistical methods
We will report summary statistics for demographics and
outcome data of the study participants. The assessment of
mediators is important to be able to identify the processes
by which the intervention may bring about change. The
proportion of adherence to the intervention will be re-
ported descriptively with 95% confidence intervals. Graph-
ical illustration will be used to check distributions of
outcome data. As an exploratory trial, the primary outcome
measures will be feasibility and acceptability. Results will be
presented using point estimates, 95% confidence intervals
and p values. The primary statistical analysis will be on an
intention-to-treat basis, and the primary analysis will use
the complete case data set. Exploratory analyses will be
used to investigate the impact of individual demographic
factors as well as theoretical mediators (i.e. disease/fatigue
severity) on the intervention effect using appropriate cor-
relation coefficients.
Feasibility
Feasibility will be analysed through evaluation of eligibil-
ity, recruitment and retention (in line with CONSORT ex-
tension recommendations). Adherence to intervention
will also be assessed. Completeness of outcome measures
will be reported, and 80% would be considered appropri-
ate for each measure. Feasibility will be determined and
estimates of effect size and outcome variability will be cal-
culated to inform future planned studies.
Eligibility
Eligibility will be assessed through screening logs. We
will report on the proportion of screened participants
who were deemed eligible for the study, and summarise
the reasons for ineligibility.
Recruitment
Recruitment will be evaluated based on the final number
of participants who were successfully consented and
randomised.
Retention (i.e. assessments)
Retention will be measured by evaluating the proportion
of participants who were lost to follow-up.
Adherence
Successful adherence to the intervention will be defined as
at least 75% of the participants having completed cocoa
consumption [33]. We will assess discontinuation of the
intervention. Further aspects of adherence will be
measured by the percentage of fatigue texts completed by
participants and those who wore the accelerometer-axivity
watches. If the proportion is less than this but greater than
65%, we will consider adjusting the intervention to increase
this in future investigations. An adherence rate lower than
this would require substantial changes to the intervention
and therefore require further piloting.
Acceptability
The acceptability of the intervention will be measured
through the end-of-study interview, which uses questions
to measure the extent to which participants found the
intervention and materials useful, enjoyable and beneficial.
Exploratory analyses will be used to investigate the im-
pact of individual demographic factors as well as theor-
etical mediators on the short-term benefit of the
intervention, using appropriate correlation coefficients.
A generalised linear model analysis will investigate
whether fatigue differed between the treatment arms. This
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will be extended to joint modelling of both fatigue and
physical functioning if there is a significant difference in
the reported fatigue. Data may be transformed to improve
model fit, or different regression approaches used (e.g.
negative binomial or Poisson regression).
Trial sponsorship
OBU is the sponsor for the trial.
Funding
Funding for the trial was granted from the Multiple
Sclerosis Society.
Trial status
The first participant was consented on the 15th of June
2016. The trial is currently recruiting until the 31st of
August 2017.
Discussion
This study sets out to estimate the extent of the im-
pact and feasibility of implementing flavonoids as an
intervention for fatigue management in PwMS. Pa-
tients, carers and clinicians agree that fatigue is one
of the most debilitating symptoms, and while there is
no effective drug therapy to treat fatigue in this group
and no clear understanding of the underpinning
mechanism, diet offers a logical method to act on
some of the suggested possible mechanisms [3–7] and
reduce fatigue severity and improve activity and mo-
bility in PwMS. Previous studies have been mostly ob-
servational cross-sectional studies with inconclusive
results for determining the best nutritional interven-
tions for symptom management in MS. Unlike in the
field of physiotherapy/exercise science where there are
a number of interventional studies and burgeoning
evidence of optimal and safe exercise interventions to
support symptom management, there is a paucity of
good quality trials investigating dietary interventions
and extremely limited evidence. There are also no
other methods described for controlling and imple-
menting diet so this study will provide a framework
for dietary intervention and monitoring in PwMS and
other groups. This study is therefore designed not
only to pave way for a fully powered, targeted, well-
controlled, cost-effective intervention study with minimal
risks but also to develop methodology for implementing
dietary trials in people with MS and other neurological
conditions. The current application also focuses on the
priority to refine existing treatments from other condi-
tions as treatments for MS and is based on successful re-
search on fatigue in people with CFS. The results from
this study will be generalisable to those with RRMS and
high levels of fatigue, and therefore, future trials will need
to explore generalisability to other types of MS and for
those with lower fatigue.
There is limited infrastructure in place to support the
development of high-quality research and evaluation of
nutritional interventions and exposures. This project also
brings together key stakeholders enabling an interdiscip-
linary team involving clinicians, researchers and PwMS to
ensure the trial is performed and disseminated to the best
of its ability, leading to further collaborations and funding.
This feasibility trial is utilising a range of outcome mea-
sures in order to gather all relevant and comprehensive
data to produce results that inform a follow-on trial. This
project takes a multi-pronged approach to measuring fa-
tigue, understanding the basis of differences in fatigability
and assessing potential interventions.
Risk management
The addition of a cocoa beverage to the diet of pwMS
may cause concern for those taking part due to the added
calories. By consuming cocoa in a concentrated drink
form, the total calorie content is reduced compared to if a
chocolate bar was consumed and, therefore, weight gain
will not be of concern and we are recording weight at the
beginning and end of the intervention. There has also
been reporting of a reduction in appetite after dark cocoa
consumption, and this will be monitored during the 24-h
recall at each visit. Research, to date, has not reported any
potential side effects of cocoa or any allergies associated
with its consumption. The flavonoid-rich pure cocoa
drink will be matched to the control drink for macronutri-
ents, theobromine and caffeine and will be at safe levels of
intake. There is a risk of participants burning themselves
adding the rice milk to the drink; however, people rou-
tinely make hot drinks in their homes and, therefore, this
risk is not above the risks involved in daily activity. Partici-
pants will be asked about their habitual diet using a 24-h
recall at baseline, assessment 1 and assessment 2. This will
monitor any significant or potentially harmful changes to
the diet that are taking place throughout the trial.
It is possible that a participant could trip or fall during
the 6-min walk test. However, the team routinely adminis-
ters walking tests with people with neurological conditions
including people with MS (pwMS) with no AEs. Question-
naires used in the study may cause mild distress to partici-
pants; however, they are all commonly used questionnaires.
Should a participant become distressed, we would stop the
assessment until and if the participant feels able to
continue.
The blood samples will be taken with minimal discom-
fort. Some individuals may experience an increased sen-
sitivity on the forearm, but this will disappear in 1 to
2 days and should not affect a participant’s work. Minor
risks are associated with sampling blood, including faint-
ing, infection and bruising. Sampling will be performed
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by a trained phlebotomist, thus reducing the risks sig-
nificantly. A first aid provider will be available at all
times during testing. There will be a designated clean
area where blood will be taken. Clinical waste proce-
dures will be followed at all times.
Attending baseline and final assessment at OBU will pose
some risk in travelling to the site. However, participants will
be provided with transport and any other assistance that
they need in order to feel comfortable and safe. To reduce
participant burden, they will have the option of having the
researchers come to their homes in order to take measures
at assessment 2. The OBU lone working policy will be ap-
plied. Researcher will risk assess on arrival at a person’s
home and terminate the visit if there are any causes for
concern. The researcher will establish a contact point with
the research team at OBU so that researcher’s whereabouts
are known. A mobile phone text message will be sent to
confirm safe arrival at the participant’s home and on leaving
the home. Researchers will always ensure that participants
are fully aware of the time and date that they will be attend-
ing a home visit.
Feasibility
We will consider the acceptability of the intervention to
participants, the ability of centres to recruit participants,
the willingness of participants to be randomised, the
number of eligible participants, the acceptability of the
measures and the time taken to collect data.
From a design perspective, we have explicitly considered
the burden with respect to timings of assessments and
intervention sessions. AEs will be systematically docu-
mented, and if participants choose to discontinue the
intervention, sites are encouraged to continue with out-
come assessments wherever possible. Finally, data moni-
toring will be extensive to ensure minimisation of missing
forms or data, and analysis will consider imputation
methods as required. The data gathered here will inform
the design (including sample size calculations) and deliv-
ery of a confirmatory phase III trial. In order to ensure re-
peatability in confirmatory trials, reporting will follow the
template for intervention description and replication
(TIDieR) reporting guidelines for description of interven-
tions, and the Consolidated Standards of Reporting Trials
(CONSORT) extension for non-pharmacological interven-
tions. The possibility of refining measures will be consid-
ered by the research team, and key features of the
feasibility trial will be considered for future work.
The end of the trial will be considered as the date
on which the last participant has completed his or
her final assessment.
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